Sunday, 1 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Capacity Expansion

Aurobindo Pharma Capacity Expansion: ₹1,395 Cr Investment

Aurobindo Pharma's subsidiary, TheraNym Biologics, will invest approximately ₹1395.0 Crore (USD 150M) to establish a new large-scale mammalian manufacturing facility ('Unit 2'). This greenfield project expands an existing CMO relationship with Merck Sharpe & Dohme (MSD) and will house 60 KL of bioreactor capacity.

Key figures
Value₹1,395 Cr
Source

BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Aurobindo Pharma Ltd: key numbers

Share price
₹1,681.40
Market cap
₹97,656 Cr
Revenue (annual)
₹33,653 Cr
Net profit (annual)
₹3,505 Cr
P/E (TTM)
24.8×Sector 45.9×
Promoter holding
51.88%+0.00% QoQ
FII holding
17.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Aurobindo Pharma Ltd

All →

Other capacity expansion announcements

All →